Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oragenics' weight loss agent LPT3-04 has demonstrated significant reduction in body weight in the trial.
Subscribe to our email newsletter
LPT3-04 is a natural occurring dietary substance with proven safety and tolerance profile.
The double-blind placebo-controlled human clinical study randomized 32 healthy, overweight and mildly obese adult volunteers to receive daily supplementation of LPT3-04 over a twelve-week period.
The study was conducted at the Miami Research Associates (MRA) clinical research facilities in Miami, US.
MRA investigators reported that there were no safety concerns and no reports of serious adverse events with daily supplementation of LPT3-04.
Earlier animal safety and efficacy studies confirmed that LPT3-04 has the potential to support weight loss in overweight men and women.
Oragenics CEO John N Bonfiglio said the reported weight loss appears to relate to LPT3-04’s ability to increase programmed cell death of white fat cells.
"The company is currently seeking partners to further develop this technology and commercialize food and beverage products that encourage the weight management of both humans and companion pets," Bonfiglio added.